Review





Similar Products

bone morphogenetic protein 4  (Sino Biological)
94
Sino Biological bone morphogenetic protein 4
Bone Morphogenetic Protein 4, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bone morphogenetic protein 4/product/Sino Biological
Average 94 stars, based on 1 article reviews
bone morphogenetic protein 4 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
bmp4  (MedChemExpress)
94
MedChemExpress bmp4
Bmp4, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bmp4/product/MedChemExpress
Average 94 stars, based on 1 article reviews
bmp4 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
recombinant bmp4 protein  (MedChemExpress)
94
MedChemExpress recombinant bmp4 protein
( A ) Western blot results for the detection of pSmad5, pSmad1/5/9, and other proteins after enalapril treatment. ( B ) GSEA showing the enrichment of the BMP signaling pathway after enalapril treatment. NES, normalized enrichment score. ES, enrichment score. ( C ) Profile of pSmad1/5/9 enrichment at the TSS regions in the control group (Ctrl) and the enalapril-treated group (Enalapril). ( D ) Heatmap of cell cycle (green) and SASP-related genes (purple) in the control group (Ctrl), BMP receptor inhibitor-treated group (LDN193189, LDN), and enalapril and BMP receptor inhibitor-cotreated group (EP+LDN). ( E ) Western blot analysis showing the protein levels of pSmad1/5/9, p16, and p21 in response to different combinations of enalapril, a BMP receptor inhibitor (LDN193189, LDN), and <t>BMP4.</t> ( F ) Senescence-associated β-galactosidase (SA-β-Gal) staining (left) and corresponding ratio statistical chart (right) of IMR90 cells treated with different combinations of enalapril, a BMP receptor inhibitor (LDN193189, LDN), and BMP4. Scale bars, 200 μm. Enlarged scale bars, 100 μm. ( G ) Ki67 immunofluorescence experiment (left) and intensity statistical chart (right) of IMR90 cells treated with different combinations of enalapril, a BMP receptor inhibitor (LDN193189, LDN), and BMP4. Scale bars, 80 μm. Enlarged scale bars, 40 μm. A two-tailed t-test was employed; ns indicates no significant difference, * p <0.05, ** p <0.01, *** p <0.001. Figure 2—source data 1. PDF file containing original western blots for , indicating the relevant bands and treatments. Figure 2—source data 2. Original files for western blot analysis displayed in .
Recombinant Bmp4 Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant bmp4 protein/product/MedChemExpress
Average 94 stars, based on 1 article reviews
recombinant bmp4 protein - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
human recombinant bone morphogenetic protein 4 (bmp4)  (STEMCELL Technologies Inc)
90
STEMCELL Technologies Inc human recombinant bone morphogenetic protein 4 (bmp4)
( A ) Western blot results for the detection of pSmad5, pSmad1/5/9, and other proteins after enalapril treatment. ( B ) GSEA showing the enrichment of the BMP signaling pathway after enalapril treatment. NES, normalized enrichment score. ES, enrichment score. ( C ) Profile of pSmad1/5/9 enrichment at the TSS regions in the control group (Ctrl) and the enalapril-treated group (Enalapril). ( D ) Heatmap of cell cycle (green) and SASP-related genes (purple) in the control group (Ctrl), BMP receptor inhibitor-treated group (LDN193189, LDN), and enalapril and BMP receptor inhibitor-cotreated group (EP+LDN). ( E ) Western blot analysis showing the protein levels of pSmad1/5/9, p16, and p21 in response to different combinations of enalapril, a BMP receptor inhibitor (LDN193189, LDN), and <t>BMP4.</t> ( F ) Senescence-associated β-galactosidase (SA-β-Gal) staining (left) and corresponding ratio statistical chart (right) of IMR90 cells treated with different combinations of enalapril, a BMP receptor inhibitor (LDN193189, LDN), and BMP4. Scale bars, 200 μm. Enlarged scale bars, 100 μm. ( G ) Ki67 immunofluorescence experiment (left) and intensity statistical chart (right) of IMR90 cells treated with different combinations of enalapril, a BMP receptor inhibitor (LDN193189, LDN), and BMP4. Scale bars, 80 μm. Enlarged scale bars, 40 μm. A two-tailed t-test was employed; ns indicates no significant difference, * p <0.05, ** p <0.01, *** p <0.001. Figure 2—source data 1. PDF file containing original western blots for , indicating the relevant bands and treatments. Figure 2—source data 2. Original files for western blot analysis displayed in .
Human Recombinant Bone Morphogenetic Protein 4 (Bmp4), supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human recombinant bone morphogenetic protein 4 (bmp4)/product/STEMCELL Technologies Inc
Average 90 stars, based on 1 article reviews
human recombinant bone morphogenetic protein 4 (bmp4) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
bone morphogenetic protein 4 bmp4  (MedChemExpress)
94
MedChemExpress bone morphogenetic protein 4 bmp4
( A ) Western blot results for the detection of pSmad5, pSmad1/5/9, and other proteins after enalapril treatment. ( B ) GSEA showing the enrichment of the BMP signaling pathway after enalapril treatment. NES, normalized enrichment score. ES, enrichment score. ( C ) Profile of pSmad1/5/9 enrichment at the TSS regions in the control group (Ctrl) and the enalapril-treated group (Enalapril). ( D ) Heatmap of cell cycle (green) and SASP-related genes (purple) in the control group (Ctrl), BMP receptor inhibitor-treated group (LDN193189, LDN), and enalapril and BMP receptor inhibitor-cotreated group (EP+LDN). ( E ) Western blot analysis showing the protein levels of pSmad1/5/9, p16, and p21 in response to different combinations of enalapril, a BMP receptor inhibitor (LDN193189, LDN), and <t>BMP4.</t> ( F ) Senescence-associated β-galactosidase (SA-β-Gal) staining (left) and corresponding ratio statistical chart (right) of IMR90 cells treated with different combinations of enalapril, a BMP receptor inhibitor (LDN193189, LDN), and BMP4. Scale bars, 200 μm. Enlarged scale bars, 100 μm. ( G ) Ki67 immunofluorescence experiment (left) and intensity statistical chart (right) of IMR90 cells treated with different combinations of enalapril, a BMP receptor inhibitor (LDN193189, LDN), and BMP4. Scale bars, 80 μm. Enlarged scale bars, 40 μm. A two-tailed t-test was employed; ns indicates no significant difference, * p <0.05, ** p <0.01, *** p <0.001. Figure 2—source data 1. PDF file containing original western blots for , indicating the relevant bands and treatments. Figure 2—source data 2. Original files for western blot analysis displayed in .
Bone Morphogenetic Protein 4 Bmp4, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bone morphogenetic protein 4 bmp4/product/MedChemExpress
Average 94 stars, based on 1 article reviews
bone morphogenetic protein 4 bmp4 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
bone morphogenetic protein 4 (bmp4)  (PeproTech)
90
PeproTech bone morphogenetic protein 4 (bmp4)
( A ) Western blot results for the detection of pSmad5, pSmad1/5/9, and other proteins after enalapril treatment. ( B ) GSEA showing the enrichment of the BMP signaling pathway after enalapril treatment. NES, normalized enrichment score. ES, enrichment score. ( C ) Profile of pSmad1/5/9 enrichment at the TSS regions in the control group (Ctrl) and the enalapril-treated group (Enalapril). ( D ) Heatmap of cell cycle (green) and SASP-related genes (purple) in the control group (Ctrl), BMP receptor inhibitor-treated group (LDN193189, LDN), and enalapril and BMP receptor inhibitor-cotreated group (EP+LDN). ( E ) Western blot analysis showing the protein levels of pSmad1/5/9, p16, and p21 in response to different combinations of enalapril, a BMP receptor inhibitor (LDN193189, LDN), and <t>BMP4.</t> ( F ) Senescence-associated β-galactosidase (SA-β-Gal) staining (left) and corresponding ratio statistical chart (right) of IMR90 cells treated with different combinations of enalapril, a BMP receptor inhibitor (LDN193189, LDN), and BMP4. Scale bars, 200 μm. Enlarged scale bars, 100 μm. ( G ) Ki67 immunofluorescence experiment (left) and intensity statistical chart (right) of IMR90 cells treated with different combinations of enalapril, a BMP receptor inhibitor (LDN193189, LDN), and BMP4. Scale bars, 80 μm. Enlarged scale bars, 40 μm. A two-tailed t-test was employed; ns indicates no significant difference, * p <0.05, ** p <0.01, *** p <0.001. Figure 2—source data 1. PDF file containing original western blots for , indicating the relevant bands and treatments. Figure 2—source data 2. Original files for western blot analysis displayed in .
Bone Morphogenetic Protein 4 (Bmp4), supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bone morphogenetic protein 4 (bmp4)/product/PeproTech
Average 90 stars, based on 1 article reviews
bone morphogenetic protein 4 (bmp4) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
human bmp4  (MedChemExpress)
94
MedChemExpress human bmp4
( A ) Western blot results for the detection of pSmad5, pSmad1/5/9, and other proteins after enalapril treatment. ( B ) GSEA showing the enrichment of the BMP signaling pathway after enalapril treatment. NES, normalized enrichment score. ES, enrichment score. ( C ) Profile of pSmad1/5/9 enrichment at the TSS regions in the control group (Ctrl) and the enalapril-treated group (Enalapril). ( D ) Heatmap of cell cycle (green) and SASP-related genes (purple) in the control group (Ctrl), BMP receptor inhibitor-treated group (LDN193189, LDN), and enalapril and BMP receptor inhibitor-cotreated group (EP+LDN). ( E ) Western blot analysis showing the protein levels of pSmad1/5/9, p16, and p21 in response to different combinations of enalapril, a BMP receptor inhibitor (LDN193189, LDN), and <t>BMP4.</t> ( F ) Senescence-associated β-galactosidase (SA-β-Gal) staining (left) and corresponding ratio statistical chart (right) of IMR90 cells treated with different combinations of enalapril, a BMP receptor inhibitor (LDN193189, LDN), and BMP4. Scale bars, 200 μm. Enlarged scale bars, 100 μm. ( G ) Ki67 immunofluorescence experiment (left) and intensity statistical chart (right) of IMR90 cells treated with different combinations of enalapril, a BMP receptor inhibitor (LDN193189, LDN), and BMP4. Scale bars, 80 μm. Enlarged scale bars, 40 μm. A two-tailed t-test was employed; ns indicates no significant difference, * p <0.05, ** p <0.01, *** p <0.001. Figure 2—source data 1. PDF file containing original western blots for , indicating the relevant bands and treatments. Figure 2—source data 2. Original files for western blot analysis displayed in .
Human Bmp4, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human bmp4/product/MedChemExpress
Average 94 stars, based on 1 article reviews
human bmp4 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

Image Search Results


( A ) Western blot results for the detection of pSmad5, pSmad1/5/9, and other proteins after enalapril treatment. ( B ) GSEA showing the enrichment of the BMP signaling pathway after enalapril treatment. NES, normalized enrichment score. ES, enrichment score. ( C ) Profile of pSmad1/5/9 enrichment at the TSS regions in the control group (Ctrl) and the enalapril-treated group (Enalapril). ( D ) Heatmap of cell cycle (green) and SASP-related genes (purple) in the control group (Ctrl), BMP receptor inhibitor-treated group (LDN193189, LDN), and enalapril and BMP receptor inhibitor-cotreated group (EP+LDN). ( E ) Western blot analysis showing the protein levels of pSmad1/5/9, p16, and p21 in response to different combinations of enalapril, a BMP receptor inhibitor (LDN193189, LDN), and BMP4. ( F ) Senescence-associated β-galactosidase (SA-β-Gal) staining (left) and corresponding ratio statistical chart (right) of IMR90 cells treated with different combinations of enalapril, a BMP receptor inhibitor (LDN193189, LDN), and BMP4. Scale bars, 200 μm. Enlarged scale bars, 100 μm. ( G ) Ki67 immunofluorescence experiment (left) and intensity statistical chart (right) of IMR90 cells treated with different combinations of enalapril, a BMP receptor inhibitor (LDN193189, LDN), and BMP4. Scale bars, 80 μm. Enlarged scale bars, 40 μm. A two-tailed t-test was employed; ns indicates no significant difference, * p <0.05, ** p <0.01, *** p <0.001. Figure 2—source data 1. PDF file containing original western blots for , indicating the relevant bands and treatments. Figure 2—source data 2. Original files for western blot analysis displayed in .

Journal: eLife

Article Title: Enalapril mitigates senescence and aging-related phenotypes in human cells and mice via pSmad1/5/9-driven antioxidative genes

doi: 10.7554/eLife.104774

Figure Lengend Snippet: ( A ) Western blot results for the detection of pSmad5, pSmad1/5/9, and other proteins after enalapril treatment. ( B ) GSEA showing the enrichment of the BMP signaling pathway after enalapril treatment. NES, normalized enrichment score. ES, enrichment score. ( C ) Profile of pSmad1/5/9 enrichment at the TSS regions in the control group (Ctrl) and the enalapril-treated group (Enalapril). ( D ) Heatmap of cell cycle (green) and SASP-related genes (purple) in the control group (Ctrl), BMP receptor inhibitor-treated group (LDN193189, LDN), and enalapril and BMP receptor inhibitor-cotreated group (EP+LDN). ( E ) Western blot analysis showing the protein levels of pSmad1/5/9, p16, and p21 in response to different combinations of enalapril, a BMP receptor inhibitor (LDN193189, LDN), and BMP4. ( F ) Senescence-associated β-galactosidase (SA-β-Gal) staining (left) and corresponding ratio statistical chart (right) of IMR90 cells treated with different combinations of enalapril, a BMP receptor inhibitor (LDN193189, LDN), and BMP4. Scale bars, 200 μm. Enlarged scale bars, 100 μm. ( G ) Ki67 immunofluorescence experiment (left) and intensity statistical chart (right) of IMR90 cells treated with different combinations of enalapril, a BMP receptor inhibitor (LDN193189, LDN), and BMP4. Scale bars, 80 μm. Enlarged scale bars, 40 μm. A two-tailed t-test was employed; ns indicates no significant difference, * p <0.05, ** p <0.01, *** p <0.001. Figure 2—source data 1. PDF file containing original western blots for , indicating the relevant bands and treatments. Figure 2—source data 2. Original files for western blot analysis displayed in .

Article Snippet: Recombinant BMP4 protein (MCE, HY-P7007) was dissolved in sterile ddH 2 O to prepare a 100 μg/mL stock solution.

Techniques: Western Blot, Control, Staining, Immunofluorescence, Two Tailed Test

( A ) Western blot analysis showing the changes in protein levels following BMP4 treatment. ( B ) Senescence-associated β-galactosidase (SA-β-Gal) staining (left) and corresponding ratio analysis chart (right) following BMP4 treatment. Scale bars, 200 μm. Enlarged scale bars, 100 μm. ( C ) Ki67 immunofluorescence (right) and corresponding ratio analysis chart (left) following BMP4 treatment. Scale bars, 80 μm. Enlarged scale bars, 40 μm. A two-tailed t-test was employed, ** p <0.01, **** p <0.0001. Figure 2—figure supplement 2—source data 1. PDF file containing original western blots for , indicating the relevant bands and treatments. Figure 2—figure supplement 2—source data 2. Original files for western blot analysis displayed in .

Journal: eLife

Article Title: Enalapril mitigates senescence and aging-related phenotypes in human cells and mice via pSmad1/5/9-driven antioxidative genes

doi: 10.7554/eLife.104774

Figure Lengend Snippet: ( A ) Western blot analysis showing the changes in protein levels following BMP4 treatment. ( B ) Senescence-associated β-galactosidase (SA-β-Gal) staining (left) and corresponding ratio analysis chart (right) following BMP4 treatment. Scale bars, 200 μm. Enlarged scale bars, 100 μm. ( C ) Ki67 immunofluorescence (right) and corresponding ratio analysis chart (left) following BMP4 treatment. Scale bars, 80 μm. Enlarged scale bars, 40 μm. A two-tailed t-test was employed, ** p <0.01, **** p <0.0001. Figure 2—figure supplement 2—source data 1. PDF file containing original western blots for , indicating the relevant bands and treatments. Figure 2—figure supplement 2—source data 2. Original files for western blot analysis displayed in .

Article Snippet: Recombinant BMP4 protein (MCE, HY-P7007) was dissolved in sterile ddH 2 O to prepare a 100 μg/mL stock solution.

Techniques: Western Blot, Staining, Immunofluorescence, Two Tailed Test